Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 597 participants.

Also called NCT05886088

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 597 participants (planned count) (from the registry)
Sponsor
EMS (from the registry)
Registry
  • NCT NCT05886088
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT05886088. Randomized; quadruple masking; primary purpose treatment. Start 2024-02 (anticipated); primary completion 2026-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus
Acronym
DÁLIA
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
LID104
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Linagliptin
Lead sponsor
EMS (class: industry)

Record details

Record id
cardio:ct-nct05886088
Content hash
72d6b25813519cf6bf52bee72a0650d3c768ad56207aca4f8a690197a42c2a22